Beneficial effect of interferon-β 1b treatment in patients with relapsing–remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 148 (1-2) , 206-211
- https://doi.org/10.1016/j.jneuroim.2003.12.002
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Neutralising antibodies to interferon beta during the treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Soluble HLA:Human Immunology, 1998
- Soluble HLA class I and class II antigens in patients with multiple sclerosisTissue Antigens, 1998
- Pharmacodynamics of Recombinant IFN-β During Long-Term Treatment of Malignant MelanomaJournal of Interferon & Cytokine Research, 1996
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Serum HLA class I antigens: markers and modulators of an immune response?Immunology Today, 1995
- Quantitation of soluble HLA class I heterodimers and β2-microglobulin in patients with active pulmonary tuberculosisHuman Immunology, 1994
- The regulation and expression of MHC class I genesImmunology Today, 1990
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983